Attallah AM, Abdallah SO, Attallah AA, Omran MM, Farid K, Nasif WA, Shiha GE, Abdel-Aziz AF, Rasafy N, Shaker YM

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 44-53
Archivo PDF: 168.82 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40.

2. Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatol 2002; 36:1039.

3. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. WJ Gastroenterol 2010; 16: 4784-91.

4. Straub BK, Schirmacher P. Pathology and biopsy assessment of non-alcoholic fatty liver disease. Dig Dis 2010; 28: l97-202.

5. Chang DY, Shin EC. Immune-based therapy for chronic hepatitis C. J Leukoc Biol 2009; 86: 33-9.

6. de Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. Vox Sang 2009; 97: 1-12.

7. Yeshua H, Oren R. Non invasive assessment of liver fibrosis. Ann Transplant 2008; 13: 5-11.

8. Abenavoli L, Addolorato G, Riccardi L, Gasbarrini A, Gasbarrini G, Rapaccini GL. Elastography assessment in patients with chronic HCV infection. Int J Clin Pract 2008; 62: 1108-12.

9. Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008; 38: 762-9.

10. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. WJ Gastroenterol 2006; 12: 3682-94.

11. Han KH, Yoon KT. New diagnostic method for liver fibrosis and cirrhosis. Lntervirol 2008; 51: 11-6.

12. Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroenterol Clin Biol 2008; 32: 73-9.

13. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-90.

14. Helvaci M, Ozkaya B, Ozbal E, Ozinel S, Yaprak I. Efficacy of interferon therapy on serum fibronectin levels in children with chronic hepatitis B infection. Pediatr Int 1999; 41: 270-3.

15. Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol 2010; 45: 349-56.

16. Attallah AM, Zahran F, Ismail H, Omran MM, El-Dosoky I, Shiha GE. Immunochemical identification and detection of serum fibronectin in liver fibrosis patients with chronic hepatitis C. J Immunoassay lmmunochem 2007; 28: 331-42.

17. Attallah AM, Ismail H, Shiha GE, Abou-Dobara MI, El-Sherbiny RE, El-Dosoky I. Immunochemical identification and partial characterization of a native hepatitis C viral nonstructural 4 antigen in sera of HCV infected patients. Clin Chim Acta 2008; 388: 115-22.

18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOS VIRC groups. Lancet 1997; 349: 825-32.

19. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol 2003; 38: 518- 26.

20. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-9.

21. Tamkun JW, Hynes RO. Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 1983; 258: 4641-7.

22. Benyon D, Arthur MJP. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001; 21: 373-84.

23. Junge J, Horn T, Christoffersen P. The occurrence and significance of fibronectin in livers from chronic alcoholics. An immunohistochemical study of early alcoholic liver injury. APMIS 1988; 96: 56-61.

24. Tormihira M. Changes in plasma vitronectin, fibronectin, and serum laminin P1 levels and immunohistochemical study of vitronectin in the liver of patients with chronic liver diseases. Fukuoka lgaku Zasshi 1991; 82: 21-30.

25. Simon K, Zalewska M, Gladysz A, Rotter K, Piszko P, Glowacki A. A Plasma fibronectin in chronic liver diseasemarker of fibrosis? Przegl Lek 1995; 52: 129-32.

26. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 1918-22.

27. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of ‘hypersplenic’ thrornbocytopenia. J Clin Invest 1966; 45: 645-57.

28. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatol 1985; 5: 367-75.

29. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008; 9: 1092-101.

30. Stolz A, Kaplowitz N. Biochemical tests for liver disease. In: Zakim D, Boyer TD (eds.). Hepatology. A Textbook of Liver Disease, Vol. 1. Philadelphia PA: Saunders; 1990, p. 637-67.

31. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.

32. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E, Gentile I et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001; 47: 1696-700.

33. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49: 450-4.

34. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P, et al. FIBROSTIC study group: Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21.

35. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.

36. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007; 120: 280.

37. Wong VW, Chan HL. Transient elastography. J Gastroenterol Hepatol 2010; 25: 1726-31.

38. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 2011; 5: 625-34.

39. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatol 2011; 53: 2107-10.

40. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007; 46: 628-34.

41. Takemoto R, Nakamuta M, Aoyagi Y, et al. Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Dig Dis 2009; 10: 145-8.

42. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9: 43-51.

43. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatol 2004; 39: 1147-71.